Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Net Income (2023 - 2025)

CG Oncology's Net Income history spans 3 years, with the latest figure at -$41.3 million for Q4 2025.

  • For Q4 2025, Net Income fell 29.72% year-over-year to -$41.3 million; the TTM value through Dec 2025 reached -$160.8 million, down 82.69%, while the annual FY2025 figure was -$160.8 million, 82.69% down from the prior year.
  • Net Income reached -$41.3 million in Q4 2025 per CGON's latest filing, up from -$43.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$8.7 million in Q1 2023 to a low of -$43.7 million in Q3 2025.
  • Average Net Income over 3 years is -$24.8 million, with a median of -$19.7 million recorded in 2024.
  • The largest YoY upside for Net Income was 29.72% in 2025 against a maximum downside of 119.05% in 2025.
  • A 3-year view of Net Income shows it stood at -$16.6 million in 2023, then crashed by 92.16% to -$31.8 million in 2024, then decreased by 29.72% to -$41.3 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Net Income are -$41.3 million (Q4 2025), -$43.7 million (Q3 2025), and -$41.4 million (Q2 2025).